Gossamer Bio Stock Price, News & Analysis

Onxeo S.A. has appointed Bryan Giraudo, COO & CFO of Gossamer Bio, as an independent member of its Board of Directors, replacing Thomas Hofstaetter. Giraudo brings extensive financial expertise and a strong network in the U.S. life sciences sector. His appointment aims to strengthen Onxeo's international focus, especially in developing its innovative oncology drug, AsiDNA™, which targets DNA Damage Response (DDR). Chairwoman Shefali Agarwal and CEO Judith Greciet lauded his financial acumen and strategic insights.

Gossamer Bio reported its third quarter 2021 results, highlighting significant cash reserves of $366 million as of September 30, 2021. The company is advancing its clinical programs including Seralutinib, with phase 2 topline results now expected in H2 2022 due to COVID-19 delays. Additionally, the SHIFT-UC study has completed enrollment, with initial results anticipated in Q2 2022. R&D expenses rose to $43.2 million, while the net loss for the quarter was $60.2 million, maintaining the same per-share loss as in 2020.

Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company, will report its third quarter 2021 financial results on November 8, 2021. The management team will hold a live conference call at 4:15 p.m. ET to discuss financial results and provide a corporate update. Interested parties can join via domestic and international dial-in numbers or through a live webcast. A replay will be available for 30 days on Gossamer's website, ensuring accessibility for investors and stakeholders.

Gossamer Bio (NASDAQ: GOSS) announced two new CNS-penetrant Bruton’s tyrosine kinase (BTK) inhibitors, GB5121 and GB7208, aimed at treating central nervous system malignancies and diseases. The first-in-human trial for GB5121 is set for Q4 2021, targeting relapsed/refractory primary CNS lymphoma. GB7208 is progressing towards clinical trials with promising preclinical outcomes. Both candidates exhibit superior CNS penetration and selectivity compared to existing treatments, addressing unmet needs in oncology and neurology.

Gossamer Bio, Inc. (NASDAQ: GOSS) has scheduled a conference call and webcast for investors on October 11, 2021 at 2:30 pm ET. The event will focus on the company's new clinical product candidates in immunology, inflammation, and oncology. Management will provide insights into their pipeline and will be available for questions.

Investors can access the live webcast on Gossamer's website or dial in using the provided numbers. A replay will be available for 30 days.

Gossamer Bio, Inc. (NASDAQ: GOSS) has appointed Bryan Giraudo as Chief Operating Officer, maintaining his role as Chief Financial Officer. He joined Gossamer in May 2018 and has significantly contributed to the company's financial and organizational strength. Giraudo's promotion reflects his expanding leadership role. Before joining Gossamer, he was a Senior Managing Director at SVB Leerink and a Managing Director at Merrill Lynch's Global Healthcare Investment Banking Group. Gossamer Bio focuses on therapeutics in immunology, inflammation, and oncology.

Gossamer Bio, Inc. (Nasdaq: GOSS) reported its Q2 2021 financial results, highlighting a net loss of $59.8 million, or $0.80 per share, an improvement from a net loss of $66.9 million, or $1.00 per share in Q2 2020. As of June 30, 2021, cash, cash equivalents, and marketable securities totaled $405.9 million, projected to fund operations through H2 2023. Key clinical updates include ongoing Phase 2 studies for seralutinib and GB004, with safety data showing promise in PAH treatment. However, Gossamer will discontinue further development of GB1275.

Gossamer Bio (Nasdaq: GOSS) announced it will report its Q2 2021 financial results on August 9, 2021. The live conference call will take place at 4:30 p.m. ET, where management will discuss the results and provide a corporate update. Investors can join the call via domestic at (833) 646-0603 or international at (929) 517-9782. A replay will be available for 30 days on their website, www.gossamerbio.com. Gossamer is focused on developing therapeutics in immunology, inflammation, and oncology.

Gossamer Bio (Nasdaq: GOSS) announced its participation in the 2021 Virtual Congress of the European Crohn’s and Colitis Organisation (ECCO), taking place from July 2-3 and 8-10. On July 8, William Sandborn, M.D., will present findings from the completed Phase 1b clinical trial for GB004, an oral gut-target HIF-1α stabilizer, focusing on target engagement and pharmacodynamic biomarkers in patients with mild-to-moderate ulcerative colitis. The presentation and poster will later be accessible on Gossamer Bio's website.